Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk ...

Dexamethasone reduced the severity of ICANS but did not impact the rates of ICANS or CRS in patients with LBCL receiving axi-cel.

Transitioning the dose of axatilimab (Niktimvo) from 0.3 mg/kg every 2 weeks to 0.6 mg/kg every 4 weeks appeared feasible in ...

Combining azacitidine with venetoclax (Venclexta) significantly increased event-free survival (EFS) vs intensive induction ...

The combination of carfilzomib (Kyprolis) plus lenalidomide (Revlimid) and dexamethasone (KRd) improved progression-free ...

Blinatumomab/ponatinib increased efficacy and response rates were improved in patients with Philadelphia-positive acute lymphoblastic leukemia.

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...

The FDA has approved lisocabtagene maraleucel (liso-cel; Breyanzi) for the treatment of adult patients with relapsed or ...

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

A patient acuity model drove efficient and safe staffing through data from a natural language processing model informed by ...

The FDA has approved pirtobrutinib (Jaypirca) treatment for adults with relapsed/refractory chronic lymphocytic leukemia or ...